Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia

Inclusion Criteria: 1. 19 ≤ age ≤ 75 2. at Visit 1 1) BP: sitDBP ≥ 90mmHg 2) Cholesterol : LDL-C ≤ 250mg/dL, TG \< 400mg/dL 3. at Visit 2 : after TLC (after 4weeks) 1) BP: 80 mmHg ≤ sitDBP \< 110mmHg 2) Cholesterol : following risk category (Cardiovascular Risk category) A : CHD risk factor 0 - 1, 160mg/dL ≤ LDL-C ≤ 250mg/dL B①: CHD risk factor≥2 and 10 year risk \<10%, 160mg/dL ≤ LDL-C ≤ 250mg/dL B②: CHD risk factor≥2 and 10 year risk =10-20%, 130mg/dL ≤ LDL-C ≤ 250mg/dL C : CHD/CHD risk equivalents\* or 10 year risk\>20 ,100mg/dL ≤ LDL-C ≤ 250mg/dL 3) TG \< 400mg/dL 4. Patients understood the contents and purpose of this trial and signed informed consent form Exclusion Criteria: 1. At Visit 1, BP difference SBP ≥20mmHg or DBP ≥10mmHg 2. Tolerance or Hypersensitivity Angiotensin II receptor blocker or HMG-CoA. reductase inhibitor, Calcium channel blocker(dihydropyridine) or Multi-drug allergy 3. Fibromyalgia, myopathy, rhabdomyolysis or acute myopathy or medical history of adverse effect to statin 4. CPK normal range ≥ 3times 5. Uncontrolled primary hypothyroidism(TSH normal range ≥ 2 times) 6. Renal disease or suspected renal disease (Scr ≥ 2mg/dL, AST or ALT≥2 times) 7. Active gout or hyperuricemia(at Visit 1, uric acid \> 9mg/dL) 8. IDDM or uncontrolled diabetes mellitus (HbA1c\>9%) 9. ventricular arrhythmia 10. medical history * severe cerebrovascular disease within 6 months (cerebral infarction, cerebral hemorrhage), hypertension * encephalopathy, transient cerebral ischemic attack(TIA) * severe heart disease(heart failure of NYHA class III-IV), valvular disease of heart or myocardial infarction and unstable angina * angioplasty or coronary artery bypass graft(CABG) surgery within 6months